1h Free Analyst Time
The bronchiectasis drugs market is forecasted to grow by USD 394.1 million during 2023-2028, accelerating at a CAGR of 10.87% during the forecast period. The report on the bronchiectasis drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing cases of associated risk factors, availability of low-cost off-label generics, and surge in geriatric population.
The bronchiectasis drugs market is segmented as below:
By Product
- Antibiotics
- Expectorants
- Others
By Distribution Channel
- Offline
- Online
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the bronchiectasis drugs market covers the following areas:
- Bronchiectasis drugs market sizing
- Bronchiectasis drugs market forecast
- Bronchiectasis drugs market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global bronchiectasis drugs market: AbbVie Inc., Akorn Operating Co. LLC, Amneal Pharmaceuticals Inc., Aurobindo Pharma Ltd., Bayer AG, Boehringer Ingelheim International GmbH, DR Reddys Laboratories Ltd., Endo International PLC, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Lupin Ltd., Neopharma Corp., Pfizer Inc., Reckitt Benckiser Group PLC, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., Virtus Pharmaceuticals LLC, Wockhardt Ltd., and Zydus Lifesciences Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is growing awareness about bronchiectasis."
According to the report, one of the major drivers for this market is the increasing cases of associated risk factors.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Akorn Operating Co. LLC
- Amneal Pharmaceuticals Inc.
- Aurobindo Pharma Ltd.
- Bayer AG
- Boehringer Ingelheim International GmbH
- Dr Reddys Laboratories Ltd.
- Endo International Plc
- GlaxoSmithKline Plc
- Hikma Pharmaceuticals Plc
- Lupin Ltd.
- Neopharma Corp.
- Pfizer Inc.
- Reckitt Benckiser Group Plc
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
- Virtus Pharmaceuticals LLC
- Wockhardt Ltd.
- Zydus Lifesciences Ltd.
